Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment

J Hepatol. 2008 Apr;48(4):548-58. doi: 10.1016/j.jhep.2007.12.014. Epub 2008 Jan 28.

Abstract

Background/aims: HCV-specific T cells in acute hepatitis C with subsequent chronic evolution are dysfunctional and most of them express PD-1. The aim of the study was to investigate to what extent the antiviral T cell function can be restored by reversing T cell exhaustion by PD-1/PD-L1 blockade and to assess whether this restoration is favored by IFN-alpha treatment.

Methods: PD-1 and PD-L1 expression was studied on T cells and dendritic cells, respectively, of 14 patients with acute hepatitis C and different evolutions of infection. The effect of anti-PD-L1 was analyzed on proliferation, cytokine production and cytolytic activity of CD4 and CD8 T cells.

Results: While PD-1 expression dropped concurrently with spontaneous or IFN-alpha induced HCV-RNA decline, PD-L1 levels on dendritic cells increased during IFN-alpha treatment. Anti-PD-L1 antibodies improved expansion and cytokine production but not the cytolytic activity of HCV-specific T cells. This restoration tended to be greater at lower levels of viremia and PD-1 expression and during PEG-IFNalpha treatment.

Conclusions: PD-1/PD-L1 blockade has an immunoregulatory activity which may synergize with the antiviral effect of IFN-alpha therapy and should be thus explored further in long-lasting chronic HCV infections in the perspective of improving the efficacy of available antiviral treatments.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / drug effects*
  • Antigens, CD / metabolism
  • Antiviral Agents / therapeutic use*
  • Apoptosis Regulatory Proteins / antagonists & inhibitors*
  • Apoptosis Regulatory Proteins / metabolism
  • B7-H1 Antigen
  • Cell Proliferation / drug effects
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology
  • Dendritic Cells / pathology
  • Flow Cytometry
  • Follow-Up Studies
  • Hepacivirus / drug effects
  • Hepacivirus / genetics
  • Hepacivirus / immunology*
  • Hepatitis C Antibodies / analysis
  • Hepatitis C Antibodies / immunology
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / immunology
  • Hepatitis C, Chronic / virology*
  • Humans
  • Interferon-gamma / therapeutic use
  • Programmed Cell Death 1 Receptor
  • RNA, Viral / drug effects
  • RNA, Viral / genetics
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / pathology
  • Time Factors
  • Treatment Outcome
  • Viremia / drug therapy
  • Viremia / immunology
  • Viremia / virology*

Substances

  • Antigens, CD
  • Antiviral Agents
  • Apoptosis Regulatory Proteins
  • B7-H1 Antigen
  • CD274 protein, human
  • Hepatitis C Antibodies
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • RNA, Viral
  • Interferon-gamma